CURRICULUM

Born in Naples August 24, 1960.

Graduated in Biological Science (1986) and  PhD in “Biology and Molecular Pathology” (1993), University of Naples Federico II. Research felloship DIBIT-HSR ,San Raffaele Hospital Milan (1993-1995). Technician (VII level), University of Milan (1996-2001). Technician (D1 level) University of Milan-Bicocca (2001-2003). Assistant Professor of Anatomy, University of Milan-Bicocca (2004 at today).

Author of 34 papers on international peer-reviewed journals. Reviewer for international peer-reviewed journals

http://www.unimib.it/go/888888990/Home/Italiano/Elenco-Docenti/MILOSO-MARIAROSARIA-dipartimento-di-chirurgia-e-medicina-interdisciplinare

RESEARCH ACTIVITIES

• Study of biological properties and differentiation of mesenchymal stem cells from different tissues (bone marrow, periodontal ligament, dental pulp, adipose tissue, skin)
• Effects of Valproic Acid, Valpromide, Hibiscus sabdarifa, Berberine, Resveratrol e Baicalin on mesenchymal stem cells adipogenic and osteogenic  differentiation
• In vitro study of antitumorigenic effects of Hibiscus Sabdarifa and Baicalin
• Study of molecular mechanisms involved in antineoplastic-induced peripheral neurotoxicity

RESEARCH PROJECT

Hibiscus sabdariffa (HS) is a plant belonging to Malvacee family. Its flowers are consumed as Karkadé tea and its extract is used in folk medicine. Due to its antioxidant properties, HS extract (eHS) has recently gained attention as chemopreventive compound. In our laboratory we demonstrated that in vitro eHS impaired cell viability and prevented cell migration and invasion of RPMI 8226, a multiple myeloma cell line.

Bortezomib is a proteasome inhibitor with high efficacy for multiple myeloma but with severe peripheral neurotoxicity, leading to dose modification and severe neurological disability.

In this study  we will evaluate the antitumoral effects of eHS and Bortezomib combination in RPMI 8266 cells.  This project aims to verify if eHS is able to act in a synergistic way with Bortezomib, allowing the use of lower doses of the drug resulting in reduced neurotoxicity. After eHS + Bortezomib treatment we will evaluate RPMI 8226 cell viability, migration and invasion and the involvement of specific molecular pathways. We will analyze eHS + Bortezomib neurotoxicity in primary sensitive neurons primary cultures and organotypic cultures of dorsal root ganglia. In a second step we will evaluate in vivo the effects of eHS + Bortezomib  in a rat model.

MOST RELEVANT PUBLICATIONS

1. Foudah D, Redondo J, Caldara C, Carini F, Tredici G, Miloso M. (2013) Human mesenchymal stem cells express neuronal markers after osteogenic and adipogenic differentiation Cell Mol Biol Lett. 18:163-86.
2. Redaelli S, Bentivegna A, Foudah D, Miloso M, Redondo J, Riva G, Baronchelli S, Dalpra L, Tredici G. (2012) From cytogenomic to epigenomic profiles: monitoring the biological behavior of in vitro cultured human bone marrow mesenchymal stem cells. Stem Cell Res Ther. 3:47.
3. Donzelli E, Lucchini C, Ballarini E, Scuteri A, Carini F, Tredici G, Miloso M. (2011) ERK1 and ERK2 are involved in recruitment and maturation of human mesenchymal stem cells induced to adipogenic differentiation. J Mol Cell Biol. 3:123-131.
4. Scuteri A, Miloso M, Foudah D, Orciani M, Cavaletti G, Tredici G. (2011) Mesenchymal stem cells neuronal differentiation ability: a real perspective for nervous system repair? Curr Stem Cell Res Ther. 6:82-92
5. Miloso M., Scuteri A., Foudah D.,Tredici G. (2008) MAPKs as Mediators of Cell Fate Determination: an Approach to Neurodegenerative Diseases. Curr. Med. Chem. 6: 538-548.